Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax's (NVAX) fourth-quarter earnings and revenues miss estimates. Stock tanks on moderate revenue guidance for 2024.

Novavax (NVAX) Q4 Earnings & Sales Miss Estimates, Stock Tanks

Novavax, Inc. (NASDAQ:NVAX) shares fell over 27% on Wednesday as the Covid-19 vaccine maker warned of slowing sales ahead after missing earnings expectations in the final quarter. Revenue for the three months to December fell over 18% to US$291.3 million, the firm said on Wednesday, with analysts having expected the figure to sit at US$322 million, as per LSEG data.

Novavax sheds a quarter of value as sales look to remain pressured

The headline numbers for Novavax (NVAX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Novavax (NVAX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Novavax, Inc. (NASDAQ:NVAX) Q4 2023 Earnings Conference Call February 28, 2024 8:30 AM ET

Novavax, Inc. (NVAX) Q4 2023 Earnings Call Transcript

Novavax Inc (NASDAQ:NVAX) missed  top- and bottom-line estimates  for the fourth quarter.

Novavax Stock on Track for Worst Day Since 2022

Novavax (NASDAQ:NVAX) stock is falling hard on Wednesday as investors react to the vaccine company's earnings report for the fourth quarter of 2024. Let's dig into everything that has investors in NVAX stock disappointed today below!

NVAX Stock Alert: 9 Reasons Why Novavax Investors Are So Disappointed Today

Novavax (NVAX) came out with a quarterly loss of $1.44 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $2.28 per share a year ago.

Novavax (NVAX) Reports Q4 Loss, Lags Revenue Estimates

Novavax posts a fourth-quarter loss of $1.44 a share on revenue of $291.3 million.

Novavax Stock Sinks as Revenue Misses Estimates in ‘Transition Year'

COVID-19 vaccine maker Novavax on Wednesday said it expects revenue this year to be flat or lower as it works to improve its commercial performance and pick up market share from much larger rivals, Pfizer and Moderna

Novavax sees 2024 sales flat to lower, aims to pick up COVID vaccine market share

Novavax narrowed its losses in the quarter compared to the same period a year ago, even as demand for Covid products continues to plummet worldwide.

Novavax misses quarterly estimates, but vaccine maker narrows losses as it slashes costs

Achieved revenues in Q4 2023 of $291 million and full year 2023 of $1.0 billion Accelerating progress toward expanding pipeline  via Phase 3 COVID-19-Influenza Combination vaccine trial in second half 2024 and potential 2026 launch Rescaled global footprint with 30% total headcount reduction as compared to Q1 2023 Announced settlement with Gavi related to 2021 advance purchase agreement, removing financial uncertainty and enabling focus on shared public health mission  Provided full year 2024 total revenue guidance of $800 million to $1 billion Company to host conference call today at 8:30 a.m. ET GAITHERSBURG, Md.

Novavax Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Novavax fell behind in the coronavirus vaccine race, which has weighed heavily on its earnings potential and share price. The company is working to recover and spur growth down the road.

Has Novavax Just Solved Its Biggest Problem?

Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Novavax (NVAX) Surges 8.4%: Is This an Indication of Further Gains?

Novavax reaches a settlement related to an advance purchase agreement with Gavi.

Novavax Stock Soars 25%. A Vaccine Purchase Settlement Is One Reason Why.

Novavax (NASDAQ: NVAX ) stock is taking off on Thursday after the company reached a settlement with global vaccine organization Gavi. This settlement has Novavax agreeing to pay up to $475 million to Gavi following a dispute over payments for its Covid-19 vaccine.

NVAX Stock Climbs as Novavax Settles Covid-19 Vaccine Dispute

The total amount Novavax will pay depends on whether Gavi decides to order more Covid shots from the cash-strapped company over the next five years.

Novavax to settle dispute over canceled Covid vaccine purchase agreement

Pfizer

Novavax is making progress along the path to recovery -- and its combined COVID/flu vaccine candidate could drive growth. Pfizer offers better growth prospects than you might think, as well as a juicy dividend.

Better Bull Market Buy: Novavax vs. Pfizer

Novavax said on Thursday it has agreed to pay back international vaccine group Gavi at least $475 million in cash or vaccines by the end of 2028, settling a dispute over canceled orders that had created financial uncertainty for the U.S. maker of COVID-19 shots.

Novavax settles dispute with international vaccine group Gavi

GAITHERSBURG, Md. and GENEVA , Feb. 22, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) and Gavi, the Vaccine Alliance (Gavi) today announced they have reached a settlement related to the 2021 Advance Purchase Agreement (APA) for Novavax's prototype COVID-19 vaccine (NVX-CoV2373).

Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement

Incyte

Cassava Sciences Inc

The unpredictability of the biotech sector, highlights the inherent risks involved in certain biotech stocks to sell. 2023 was a rough year for the market, marked by a 10% plunge in the SPDR S&P Biotech ETF (XBI), alongside widespread layoffs and fundraising challenges.

Exit Now! 3 Biotech Stocks to Sell in February 2024

GAITHERSBURG, Md. , Feb. 20, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2023 financial results and operational highlights at 8:30 a.m.

Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights on February 28, 2024

After commercializing its first vaccine, Novavax is sputtering as it looks for a follow-up. Its pipeline is looking very thin, and it's being forced to scale down its operations.

Where Will Novavax Be in 10 Years?

Moderna

Maravai LifeSciences Holdings

The unpredictable nature of the biotech industry, which frequently flirts with failure, underscores the inherent risks and rewards associated with doomed biotech stocks. The journey from drug discovery to market approval is notoriously long and uncertain.

3 Doomed Biotech Stocks to Dump Before They Dive: February 2024

Chewy

Toast

Toast is growing revenue and payment volume in the double digits. Chewy is expanding into Canada, which could become a significant market for the e-commerce company.

3 Beaten-Down Growth Stocks that Could Take off in the New Bull Market

Teladoc

Novavax missed out on the biggest opportunity for COVID-19 vaccine revenue, but its investigational covid/flu vaccine may offer it future growth potential. Teladoc Health has put the focus on balancing revenue growth with its quest for profitability, and its efforts are bearing fruit.

News for Novavax Stock (NVAX)